Smoldering Myeloma Trials

Finding and understanding your clinical trial options for smoldering 'asymptomatic' myeloma can be difficult and confusing and that's where we can help. Create an account or call us today and we'll help determine which trials you may be eligible to participate in.


Create Your Account

Create your account today and get matched to eligible myeloma clinical trials.

  • Find clinical trials in your home town or around the country.
  • Find a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

THE PROMISE study is the first study to test healthy people who may be at risk for early warning signs of a blood cancer called multiple myeloma.

No travel is required to participate in this observational trial.

Learn more about this trial


Recently Updated

PRospective Multiple Myeloma Impact Study (PROMMIS)

We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.

Learn more about this trial


Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (PCROWD)

The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.

No travel is required to participate in this observational trial.

Learn more about this trial


Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.

No travel is required to participate in this observational trial.

Learn more about this trial


A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

This diagnostic trial seeks to help patients with smoldering multiple myeloma (SMM) take control of monitoring their disease.

No travel is required to participate in this observational trial.

Learn more about this trial


Recently Updated

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

Learn more about this trial


Recently Updated

A Study of two investigational drugs including PVX-410 (a Multi-Peptide Cancer Vaccine), and Citarinostat (a Histone Deacetylase Inhibitor (HDAC)) +/- Lenalidomide for Patients with Moderate or High Risk of Progression Smoldering Multiple Myeloma

This phase 1 research study is evaluating an immunotherapy as a possible treatment for moderate/high risk Smoldering Multiple Myeloma. The following investigational treatments will be involved in this study: PVX-410, Citarinostat (CC-96241) and Lenalidomide (Revlimid).

Learn more about this trial


Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)

This trial will assess the safety and efficacy of an induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed multiple myeloma. The therapy with KRdD (Kyprolis, Revlimid, dexamethasone, Darzalex) will be followed by autologous hematopoietic cell transplantation (auto-HCT) and KRdD consolidation. The hypothesis is that the KRdD therapy particularly in combination with the auto-HCT will be safe and lead to deep remission. The trial will also assess the monitoring for minimal residual disease (MRD) resurgence to determine if continuous therapy is needed or discontinuation of therapy.

Learn more about this trial


MMRF Molecular Profiling Protocol

The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.

Learn more about this trial


Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

The purpose of this study is to see if carfilzomib, lenalidomide, and dexamethasone are a safe and effective treatment for smoldering multiple myeloma.

Learn more about this trial


Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying Daratumumab as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).

Learn more about this trial


Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies

The goal of this clinical research study is to find markers that might help predict why some patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) develop multiple myeloma, while others do not.

Learn more about this trial


Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT)

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).

Learn more about this trial


Trial of Isatuximab (SAR650984) in Patients With Intermediate and High Risk Smoldering Multiple Myeloma

This phase II trial studies how well isatuximab works in treating patients with high risk smoldering plasma cell myeloma. Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of the tumor cells to grow and spread.

Learn more about this trial


Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.

Learn more about this trial


Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

The purpose of this research study is to learn whether the combination of Ixazomib, Lenalidomide, and Dexamethasone works in treating Smoldering Multiple Myeloma.

Learn more about this trial



Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM). The data may provide novel insights into anti-PDL-1-induced immunologic changes, which could potentially be relevant to its future development in Multiple Myeloma (MM) and other indications.

Learn more about this trial


Nivolumab + Lenalidomide + Dexamethasone In High-Risk Smoldering Multiple Myeloma

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.

Learn more about this trial

;